Status:
NOT_YET_RECRUITING
Exercise for Ameliorating Chemotherapy Cardiotoxicity
Lead Sponsor:
University of Hull
Collaborating Sponsors:
Hull University Teaching Hospitals NHS Trust
Conditions:
Cardiotoxicity
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
Chemotherapy is a common treatment for breast cancer but can damage the heart and blood vessels. Exercise, such as cycling, may stop chemotherapy from damaging the heart and blood vessels. Before the ...
Detailed Description
Exercise has been shown to have benefits within cardio-oncology settings and evidence supports the use of exercise as a cardioprotective method in breast cancer. Several studies demonstrate evidence f...
Eligibility Criteria
Inclusion
- Females between 18 to 75 years old.
- Confirmed early stage (I-III) ER+ HER2 - breast cancer diagnosis
- Undergoing adjuvant and neoadjuvant chemotherapy, consisting of epirubicin and cyclophosphamide (EC) followed by Docetaxel.
- No contraindications to engage in physical activity.
- Capable of giving informed consent.
- Patients able to understand and communicate in English language
Exclusion
- Participants with cognitive disorders
- Cancer metastases
- Uncontrolled or serious illnesses that might hamper patients' capacity of exercising
Key Trial Info
Start Date :
October 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06595316
Start Date
October 15 2024
End Date
December 1 2025
Last Update
September 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.